Skip to content
back

A trusted final assembly equipment partner

| 3 min read

From clinical batches to market launch: In their partnership, Ypsomed and Syntegon combine device and process expertise with the flexible RMA platform. The common goal: efficient final assembly, smooth validation, and scalable commercial production.

Discover how Syntegon and Ypsomed enable flexible final assembly, faster validation, and a smooth path from clinical batches to market launch.

Key Takeaways

  • As Ypsomed’s preferred final assembly equipment partner, Syntegon supports manufacturers across the entire device portfolio
  • The RMA assembly platform is compatible with Ypsomed's device platforms and supports both clinical and future commercial demands
  • Syntegon supports pharmaceutical and biotech companies to achieve faster validation and smoother market entry

In pharmaceutical and biotech manufacturing, even the smallest details determine the success of a project. Strict regulatory requirements, ambitious timelines, and the ultimate responsibility for patient safety leave no room for error. For pharmaceutical manufacturers and CDMOs, selecting the right final assembly equipment partner therefore depends on much more than equipment. It requires proven process expertise, profound understanding of the devices, and the ability to support smooth validation and future scale-up. This is exactly where the close collaboration between Ypsomed and Syntegon creates additional value for their shared customers.

RMA2000_03

Why expertise matters in final assembly

Because Syntegon works closely with Ypsomed across the entire portfolio of pens and autoinjectors, customers benefit from extensive device and process knowledge. The collaboration covers Ypsomed's established and future device platforms, including YpsoMate® and YpsoMate® 2.25, ensuring assembly concepts and equipment are aligned with the respective platform requirements. Regardless of the selected injection system, Syntegon consistently follows Ypsomed’s assembly documentation and procedures, while documenting every critical process step. In addition, both companies collaborate on testing and refining assembly concepts and process parameters to accelerate validation and production ramp-up. The result: greater planning reliability and fewer risks in the project lifecycle combined with the highest quality and safety standards.

Syntegon’s RMA platform – winner of the FOCUS Silver international Baden-Württemberg Design Award 2025 – has proven particularly successful in the collaboration with Ypsomed. Designed specifically for clinical trials and small production batches, the RMA combines automated assembly with manual loading and unloading. This hybrid concept offers the flexibility required for small batch sizes and different devices while ensuring repeatable and consistent assembly processes. Because the platform has been developed in close alignment with Ypsomed's device portfolio, manufacturers benefit from a solution that is already prepared for current device configurations and future developments. As project requirements evolve, additional device formats and customer-specific modules – such as container inspection or laser engraving – can be integrated, enabling a seamless transition from clinical manufacturing to high-output commercial assembly solutions.

RMA2000_260602

Strategic partnership drives progress

Syntegon’s collaboration with Ypsomed highlights how to navigate complex assembly challenges and simplify implementation for customers through continuous knowledge exchange, joint testing activities, and close alignment on current and future device platforms. Thanks to this co-creation of the final assembly equipment and the combination of device and assembly expertise with the flexibility of the RMA platform, pharmaceutical and biotech companies as well as CDMOs benefit from efficient and compliant final assembly technology and greater flexibility that translates into accelerated time-to-market.

Benefits for pharmaceutical manufacturers and CDMOs

  • Faster validation through aligned assembly processes
  • Flexible assembly solutions for evolving device portfolios
  • Compatibility with Ypsomed's platforms
  • Reduced implementation risks thanks to optimized assembly concepts
  • Scalable production concepts from clinical batches to commercial manufacturing

Would you like to learn how Syntegon can support your assembly journey? Explore our portfolio or get in touch with our experts. We look forward to co-creating your ideal final assembly concept.

YpsoMate and YpsoMate 2.25 are registered trademarks of Ypsomed AG. The product images shown are for illustrative purposes only. They are the property of Ypsomed AG and are used with permission. © 2026 Ypsomed. All rights reserved.

Interested in our pharma solutions?

Interested in our pharma solutions?

Get in touch with us!
 
Contact us

Discover more about Syntegon

A trusted final assembly equipment partner

Discover how Syntegon and Ypsomed enable flexible final assembly, faster validation, and a smooth path from clinical batches to market launch.

Sepion: new standards in tablet coating

Syntegon’s Sepion series sets new standards in tablet coating with flexible batch sizes, OEB5 containment, reproducible processes, and easy scale-up from lab to production.

Syntegon Services – at your side for the full lifecycle

Discover Syntegon Lifecycle Services for pharma production, from maintenance and spare parts to retrofits, validation, compliance, and Service Agreements.